Cencora, Inc. $COR Shares Acquired by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. increased its stake in shares of Cencora, Inc. (NYSE:COR) by 139.8% in the third quarter, HoldingsChannel reports. The firm owned 156,789 shares of the company’s stock after buying an additional 91,404 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Cencora were worth $47,076,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in Cencora in the 2nd quarter valued at about $5,154,136,000. T. Rowe Price Investment Management Inc. boosted its stake in shares of Cencora by 160.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock worth $2,262,956,000 after purchasing an additional 4,123,795 shares during the last quarter. Bank of America Corp DE purchased a new stake in shares of Cencora during the second quarter worth about $1,056,625,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Cencora during the second quarter worth about $483,772,000. Finally, Legal & General Group Plc purchased a new stake in shares of Cencora during the second quarter worth about $339,556,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Activity

In other news, EVP Elizabeth Campbell sold 11,300 shares of the company’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the sale, the executive vice president directly owned 19,455 shares in the company, valued at $6,305,754.60. This represents a 36.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.38% of the stock is owned by corporate insiders.

Cencora Trading Down 0.3%

Cencora stock traded down $0.87 during trading on Friday, reaching $340.54. The company had a trading volume of 1,978,868 shares, compared to its average volume of 1,282,490. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54. The stock’s 50 day moving average price is $320.38 and its two-hundred day moving average price is $303.34. The firm has a market capitalization of $64.99 billion, a price-to-earnings ratio of 25.30, a PEG ratio of 1.75 and a beta of 0.58. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.58 and a current ratio of 0.93.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $4.48 EPS for the quarter, topping the consensus estimate of $4.35 by $0.13. The firm had revenue of $84.75 billion during the quarter, compared to analyst estimates of $84.31 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. Cencora’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $4.00 earnings per share. As a group, equities analysts expect that Cencora, Inc. will post 17.87 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Friday, August 14th were paid a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, August 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s payout ratio is currently 17.83%.

Wall Street Analyst Weigh In

COR has been the topic of several recent analyst reports. Citigroup reissued a “buy” rating on shares of Cencora in a research note on Thursday, August 6th. Leerink Partners raised their target price on shares of Cencora from $380.00 to $388.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 7th. UBS Group lowered their target price on shares of Cencora from $430.00 to $400.00 and set a “buy” rating for the company in a research note on Friday. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $330.00 price target on shares of Cencora in a report on Tuesday, September 8th. Finally, Weiss Ratings upgraded Cencora from a “buy (b-)” rating to a “buy (b)” rating in a report on Tuesday, October 6th. Fourteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $363.81.

Cencora Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical solutions company that sources, distributes and supports the delivery of medicines and healthcare products. The company serves pharmaceutical manufacturers, healthcare providers, pharmacies and animal-health customers through its supply-chain and commercialization services.

Its activities include pharmaceutical and specialty-product distribution, manufacturer services, specialty logistics, clinical-trial support, patient-support programs and other services designed to help bring medicines to market and improve access to treatment.